Skip to main content
. 2020 Dec 21;12(12):3870. doi: 10.3390/cancers12123870

Table 1.

An overview of recent imaging studies evaluating glycans and heavily glycosylated proteins.

Preclinical Studies
Target Targeting Moiety Appl. Conjugate Cancer Type Cell Line Mouse Model or Phase Reference
Thomsen-Friedenreich PNA-coated nano-beacon FI Coumarin 6 Colon HCT 116 Subcutaneous [11]
TF peptide PET 64Cu-NO2A Breast MDA-MB-435 Subcutaneous [12]
A38C tetramer NIRF AF647 Ovarian Peritoneal Carcinomatosis IGROV-1 Orthotopic [13]
Thomsen-Nouveau 2154F12A4 mAb NIRF Qdot-800 Breast MCF7 Subcutaneous [14]
sialyl-Thomsen-Nouveau 3E8 scFv NIRF IRDye 800 Colon LS174T Orthotopic [15]
CC49 mAb HuCC49ΔCH2 mAb NIRF Cy7 Colon LS174T Subcutaneous [16]
HuCC49ΔCH2 PET 124I-DOTA Colon LS174T Subcutaneous [17]
Pre-target: CC49-HaloTag SPECT 111In-HaloTag ligands Colon LS174T Subcutaneous [18]
HuCC49ΔCH2 SPECT/γ-scin 111In Colon LS174T Subcutaneous [19]
CC49 mAb-benzamide-TCO SPECT/γ-scin 111In-Tz Colon LS174T Subcutaneous [20]
CC49 mAb-acetamide-TCO SPECT/γ-scin 111In-Tz Colon LS174T Subcutaneous [21]
Lewisa/c/x CH88.2 NIRF IRDye 800CW Colon, Pancreas HT-29, BxPC-3 Subcutaneous [22]
sialyl-Lewisa Anti-CA19-9 mAb FI AF488 dye Pancreas BxPC-3 Subcutaneous, orthotopic [23]
Anti-CA 19-9 mAb FI DyLight 650 Pancreas PDOX Orthotopic [24]
Anti-CA19-9 diabody PET 124I Pancreas BxPc-3, Capan-2, MIA PaCa-2 Subcutaneous [25]
Anti-CA19-9 cys- diabody PET 124I Pancreas BxPC-3 Subcutaneous [26]
HuMAb-5B1 mAb PET 89Zr-DFO123456 Bladder HT 1197 Subcutaneous [27]
Pre-targeted: 5B1 mAb PET 89Zr Pancreas Capan-2 Subcutaneous, orthotopic [28]
5B1 mAb-TCO PET 64Cu-NOTA-PEG7-Tz Pancreas BxPC-3, Capan-2 Subcutaneous, orthotopic [29]
PEGPH20 and HuMab-5B1 mAb PET 89Zr-DFO Pancreas BxPC3-HAS3 Subcutaneous [30]
5B1 mAb PET/NIRF 89Zr-DFO FL dye Pancreas BxPC-3, MIA PaCa-2, Suit-2 Subcutaneous, orthotopic [31]
sialyl-Lewisx sLeX-carrying liposomes NIRF Cy5.5 - Ehrlich Ascites tumor Subcutaneous [32]
Lewisy hu3S193 mAb PET SPECT/γ-scin 111In, 86Y Colon HCT-15 Subcutaneous [33]
hu3S193 diabody F(ab’)2 SPECT/γ-scin 111In-CHX-A”-DTPA Breast MCF-7 Subcutaneous [34]
GD2 ch14.18-CHO NIRF IRDye 800CW Neuroblastoma KCNR, patient-derived Orthotopic [35]
hu14.18K322A mAb PET 64Cu-p-NH2-Bn-DOTA Neuroblastoma, melanoma M21, PC-3. Subcutaneous [36]
hu14.18K322A mAb PET 64Cu-Bn-NOTA Osteosarcoma SJOS072 Subcutaneous [37]
Syndecan-1 Recombinant syndecan-1 MSOT CF750 succinyl ester Pancreas S2VP10 Orthotopic [38]
9E7.4 mAb PET 64Cu-TE2A Multiple myeloma 5T33 Subcutaneous, orthotopic [39]
Glypican-1 Glypican-1 mAb FI/MRI Gd-Au-nanoclusters Pancreas COLO-357 Subcutaneous [40]
Glypican-3 Pretarget: L5 peptide MRI SA-PEG-USPIO HCC HepG2 Subcutaneous [41]
TJ12P1 peptide NIRF Cy5.5 HCC, Prostate HepG2, PC3 Subcutaneous [42]
αGPC3 mAb PET 89Zr HCC HepG2 Orthotopic [43]
αGPC3 F(ab’)2 PET 89Zr HCC HepG2 Orthotopic [44]
MUC1 EPPT peptide MRI/NIRF Magnetic NP-Cy5.5 Colon MC38 MUC1 Orthotopic [45]
EPPT peptide MRI/NIRF Magnetic NP-Cy5.5 Breast Spontaneous Orthotopic [46]
EPPT peptide MRI/NIRF Magnetic NP-Cy5.5 Pancreas Spontaneous Orthotopic [47]
EPPT peptide MRI/NIRF Magnetic NP-Cy5.5 Colon LS174T Subcutaneous [48]
CT2 mAb NIRF DyLight 650 Pancreas Panc-1, BxPC-3 Subcutaneous, orthotopic [49]
hMUC1 mAb NIRF DyLight 755 Pancreas Capan-2 Subcutaneous [50]
CD227 mAb NIRF Fluorescein-Cy5.5 Ovary OVCAR3 Subcutaneous [51]
MUC1 aptamer NIRF MPA-PEG Breast, liver MCF-7, HepG2 Subcutaneous [52]
TAB 004 mAb NIRF ICG Breast PyMT, MMT, spontaneous Orthotopic [53]
GGSK-1/30 PET/MRI 89Zr Breast PyMTxhuMUC1 Subcutaneous [54]
PR81 mAb PET/SPECT 64Cu-DOTA Breast MCF-7 Subcutaneous [55]
PR81 mAb SPECT/γ-scin 99mTc Breast Spontaneous Orthotopic [56]
MUC1/MUC5AC Pretarget: TF10 bispecific mAb γ-scin 125I-IMP-288 Pancreas Capan-1 Subcutaneous [57]
bsPAM4 F(ab’)2 γ-scin 125I Pancreas Capan-1 Subcutaneous [58]
Pretarget: bsPAM4 F(ab’)2 γ-scin 111In-IMP-156 99mTc-IMP-192 Pancreas Capan-1 Subcutaneous [58]
MUC5AC 60C peptide MRI USPIO Colon HT-29, HCT 116 Subcutaneous [59]
MUC16 AR9.6 mAb NIRF IRDye 800CW Pancreas COLO 357, T3M4 Subcutaneous, orthotopic [60]
B43.13 mAb B43.13 scFv PET 64Cu Ovary OVCAR3, SKOV3 Subcutaneous [61]
B43.13 mAb PET 89Zr Ovary OVCAR3, SKOV3 Subcutaneous [62]
B43.13 mAb B43.13 scFv PET 18F (FBz) Ovary OVCAR3, SKOV3 Subcutaneous [63]
Clinical Studies
sialyl-Thomsen-Nouveau B72.3 mAb RIGS 125I Colon, rectum - Phase 1/2 [64]
CC49 mAb RIGS 125I Colon, rectum - Phase 1 [65]
CC49 mAb RIGS 125I Colon, rectum - Phase 1 [66]
HuCC49ΔCH2 mAb RIGS 125I Colon, rectum - Phase 1 [67]
HuCC49ΔCH2 mAb RIGS 125I Colon, rectum - Phase 1 [68]
sialyl-Lewisa HuMAb-5B1 mAb PET 89Zr-DFO Pancreas - Phase 1 [69]
B3 mAb SPECT 111In Various - Phase 1 [70]
Lewisy hu3S193 mAb SPECT/γ-scin 111In Lung - Phase 1 [71]
GD2 ch14.18 mAb γ-scin 99mTc Neuroblastoma - Phase 1 [72]
3F8 mAb γ-scin 131I Neuroblastoma - Phase 1 [73]
3F8 mAb PET 124I Neuroblastoma - Case report [74]
MUC1 C595 mAb γ-scin 111In Bladder - Phase 1 [75]
C595 mAb γ-scin 99mTc Bladder - Phase 1 [76]
MUC1/MUC5AC hPAM4 mAb γ-scin 111In Pancreas - Phase 1 [77]

Abbreviations: Appl.: application, CHX-A”-DTPA: C-functionalized Trans-cyclohexyl Diethylenetriaminepentaacetic acid, γ-scin: Gamma Scintigraphy, DFO: Desferrioxamine, DOTA: 1, 4, 7, 10-Tetraazacyclododecane-1, 4, 7, 10-Tetra-Acetic Acid, GSG: Gly-Ser-Gly, FI: Fluorescence Imaging, HCC: Hepatocellular Carcinoma, ICG: Indocyanine Green, PEG: Polyethylene Glycol, MAb: Monoclonal Antibody, MSOT: Multispectral Optoacoustic Imaging, MRI: Magnetic Resonance Imaging, NIRF: Near-Infrared Fluorescence, NP: Nanoparticle NOTA: 1, 4, 7-Triazacyclononane-1, 4, 7-Triacetic Acid, NO2A: 1, 4, 7-Triazacyclononane-1, 4-Diacetate, PDOX: Patient-Derived Orthotopic Xenograft, PNA: Arachis Hypogaea Agglutinin, RIGS: radioimmunoguided surgery, SA: Streptavidin, TCO: Trans-Cyclooctene, Tz: Tetrazine, USPIO: Ultrasmall Superparamagnetic Iron Oxide.